2011
Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials
Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovascular Interventions 2011, 4: 1209-1215. PMID: 22115661, DOI: 10.1016/j.jcin.2011.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsChi-Square DistributionCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSeverity of Illness IndexSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsReference vessel diameterEverolimus-eluting stentsPercutaneous coronary interventionLong lesionsGroup BLesion lengthMACE rateCoronary interventionSmall vesselsGroup AStent typeShort lesionsAdverse cardiac eventsHigh-risk patientsPatient-level dataLarge vesselsLower ratesCOMPARE trialLesion revascularizationEfficacy outcomesAdverse eventsCardiac eventsIndependent predictorsClinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Hermiller JB, Nikolsky E, Lansky AJ, Applegate RJ, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, Stone GW. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2011, 7: 307-13. PMID: 21729832, DOI: 10.4244/eijv7i3a54.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsPercutaneous coronary interventionSegment restenosisYounger patientsElderly patientsLower incidenceSegment late lumen lossSegment late lossSPIRIT III trialTarget vessel failureLate lumen lossDrug-eluting stentsYears of ageThree-year resultsLower ratesAge-specific mechanismsStent assignmentAngiographic outcomesCoronary interventionIII trialsInducible ischaemiaEE patientsPE patientsLumen lossNeointimal response
2010
Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Lansky AJ, Yaqub M, Hermiller JB, Smith RS, Farhat N, Caputo R, Williams JE, Sanz M, Koo K, Sood P, Sudhir K, Stone GW. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6 Suppl J: j44-52. PMID: 21930490, DOI: 10.4244/eijv6supja8.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeUnited StatesConceptsPeriprocedural myocardial infarctionSide branch occlusionBranch occlusionMyocardial infarctionStent placementDrug-eluting stent placementIndependent angiographic core laboratoryPaclitaxel-eluting stent placementLong-term adverse outcomesSPIRIT III trialPaclitaxel-eluting stentsAngiographic core laboratoryThree-year resultsLower ratesSide branchesEES armIII trialsMI ratesIndependent predictorsClinical outcomesAdverse outcomesProcedural angiogramsGrade 0Stent typeCore laboratoryEvaluation of the effects of everolimus‐eluting and paclitaxel‐eluting stents on target lesions with jailed side branches: 2‐year results from the SPIRIT III randomized trial
Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, Su X, Sudhir K, Lansky A, Simonton C, Stone G. Evaluation of the effects of everolimus‐eluting and paclitaxel‐eluting stents on target lesions with jailed side branches: 2‐year results from the SPIRIT III randomized trial. Catheterization And Cardiovascular Interventions 2010, 76: 644-651. PMID: 20506356, DOI: 10.1002/ccd.22606.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBiomarkersCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCreatine Kinase, MB FormDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionMyocardiumNecrosisPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSeverity of Illness IndexSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeUnited StatesConceptsPaclitaxel-eluting stentsMajor adverse cardiac eventsTwo-year clinical outcomesTAXUS paclitaxel-eluting stentSPIRIT III trialXience V EESAdverse cardiac eventsMyocardial infarction rateUpper normal levelCreatine kinase-MBSide branchesLower ratesThinner stent strutsPeriprocedural increasePeriprocedural myonecrosisPES patientsEES groupIII trialsInfarction rateCardiac eventsSide branch compromiseCardiac deathPES groupClinical outcomesAdverse outcomes
2009
Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials
DOLL JA, NIKOLSKY E, STONE GW, MEHRAN R, LINCOFF AM, CAIXETA A, MCLAURIN B, CRISTEA E, FAHY M, KESANAKURTHY V, LANSKY AJ. Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials. Journal Of Interventional Cardiology 2009, 22: 453-459. PMID: 19702677, DOI: 10.1111/j.1540-8183.2009.00494.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChemotherapy, AdjuvantCoronary VesselsDrug Therapy, CombinationFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsSurvival RateTreatment OutcomeWounds, PenetratingConceptsPercutaneous coronary interventionGP IIb/IIIa inhibitorsIIb/IIIa inhibitorsAdjunctive antithrombotic therapyUnfractionated heparinMyocardial infarctionAntithrombotic therapyCoronary interventionPCI trialProvisional glycoprotein (GP) IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionBaseline creatinine clearanceHORIZONS-AMI trialGP IIb/IIIaOutcomes of patientsOnly independent predictorCoronary artery perforationManagement of patientsTreatment of patientsIIb/IIIaLower ratesSimilar ratesBivalirudin monotherapyHORIZONS-AMI
2006
Drug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials
Moses JW, Stone GW, Nikolsky E, Mintz GS, Dangas G, Grube E, Ellis SG, Lansky AJ, Weisz G, Fahy M, Na Y, Russell ME, Donohoe D, Leon MB, Mehran R. Drug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials. Journal Of The American College Of Cardiology 2006, 47: 2164-2171. PMID: 16750680, DOI: 10.1016/j.jacc.2006.01.068.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsDrug-eluting stentsTarget vessel revascularizationIntermediate lesionsAngiographic restenosisMyocardial infarctionCardiac deathStent thrombosisDe novo coronary artery lesionsIntroduction of DESLate major adverse cardiac eventsEfficacy of DESNovo coronary artery lesionsBinary angiographic restenosisAdverse cardiac eventsCoronary artery lesionsCurrent treatment paradigmsTreatment of patientsIntermediate coronary lesionsBalloon-expandable stentsLower ratesEverolimus trialsRestenosis reductionTAXUS IVVessel revascularization
2004
Impact of Symptomatic Peripheral Arterial Disease on 1-Year Mortality in Patients Undergoing Percutaneous Coronary Interventions
Nikolsky E, Mehran R, Mintz G, Dangas G, Lansky A, Aymong E, Negoita M, Fahy M, Moussa I, Roubin G, Moses J, Stone G, Leon M. Impact of Symptomatic Peripheral Arterial Disease on 1-Year Mortality in Patients Undergoing Percutaneous Coronary Interventions. Journal Of Endovascular Therapy 2004, 11: 60-70. DOI: 10.1583/1545-1550(2004)011<0060:iospad>2.0.co;2.Peer-Reviewed Original ResearchSymptomatic peripheral arterial diseasePeripheral arterial diseasePercutaneous coronary interventionCoronary interventionArterial diseaseProcedural successTarget lesionsPresence of PADUrgent coronary artery bypassSmaller body surface areaMore target lesionsAtherosclerotic risk factorsChronic renal insufficiencyCoronary artery bypassFifth of patientsTransient ischemic attackHigh rateBody surface areaHigh mortality rateLower ratesFemoral hematomaHospital complicationsIschemic attackRe-PCIArtery bypassImpact of Symptomatic Peripheral Arterial Disease on 1-Year Mortality in Patients Undergoing Percutaneous Coronary Interventions
Nikolsky E, Mehran R, Mintz GS, Dangas GD, Lansky AJ, Aymong ED, Negoita M, Fahy M, Moussa I, Roubin GS, Moses JW, Stone GW, Leon MB. Impact of Symptomatic Peripheral Arterial Disease on 1-Year Mortality in Patients Undergoing Percutaneous Coronary Interventions. Journal Of Endovascular Therapy 2004, 11: 60-70. PMID: 14748627, DOI: 10.1177/152660280401100108.Peer-Reviewed Original ResearchConceptsSymptomatic peripheral arterial diseasePeripheral arterial diseasePercutaneous coronary interventionCoronary interventionArterial diseaseProcedural successTarget lesionsPresence of PADUrgent coronary artery bypassSmaller body surface areaMore target lesionsAtherosclerotic risk factorsChronic renal insufficiencyCoronary artery bypassFifth of patientsTransient ischemic attackHigh rateBody surface areaHigh mortality rateLower ratesFemoral hematomaHospital complicationsIschemic attackRe-PCIArtery bypass
2003
Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial)
Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, Mehran R, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Lansky AJ, Stone GW. Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). The American Journal Of Cardiology 2003, 92: 1091-1094. PMID: 14583362, DOI: 10.1016/j.amjcard.2003.06.005.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCross-Over StudiesDrug Administration ScheduleFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsIntraoperative ComplicationsMaleMiddle AgedMyocardial InfarctionPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesTreatment FailureConceptsAcute myocardial infarctionMyocardial infarctionGlycoprotein IIb/IIIa receptor inhibitorsUnsuccessful primary percutaneous coronary interventionIIb/IIIa receptor inhibitorsMyocardial Infarction (TIMI) grade 3 flowPrimary percutaneous coronary interventionGrade 3 flowPercutaneous coronary interventionSuboptimal angioplasty resultsAbciximab administrationCADILLAC trialIschemic complicationsControl patientsCoronary interventionProcedural complicationsAngioplasty resultsReceptor inhibitorsPrimary interventionAbciximabPatientsComplicationsInfarctionLower ratesIntervention